Miguel Hernandez Pampaloni, MD, PhD

Professor of Radiology and Medicine (Cardiology)
Director of Nuclear Cardiology for MI&T
Director, Nuclear Medicine Residency & Fellowship Programs
Professor of Clin Radiology
View full UCSF Profile

Biography

Miguel Hernandez Pampaloni, MD, PhD, is the Director of Nuclear Cardiology for the Molecular Imaging and Therapeutics Clinical Section in the Department of Radiology and Biomedical Imaging at the University of California, San Francisco. Dr. Pampaloni is responsible for overseeing nuclear cardiology and development of new techniques to evaluate cardiac metabolism and function. He will also serve as co-chair of the Cancer Center's new Molecular Imaging & Radionuclide Therapy Site Committee. Dr. Pampaloni earned his PhD in Radiological Sciences from the Universidad Complutense School of Medicine in Madrid, Spain, and he obtained his MD from the Universidad Complutense School of Medicine. Dr. Pampaloni completed a residency in Nuclear Medicine at the San Carlos Hospital in Madrid, Spain, and he completed a residency in Nuclear Medicine at the University of Pennsylvania School of Medicine. Dr. Pampaloni was a postdoctoral fellow in Cardiovascular Nuclear Medicine at the David Geffen School of Medicine at UCLA, and he was a clinical research fellow in PET Cardiology at the Imperial College in London, England. Dr. Pampaloni joined the UCSF Nuclear Medicine Section as an Assistant Professor in 2009.

Dr. Pampaloni has two main research interests: applications of molecular imaging into the cardiovascular field and oncology. He is interested in assessing the pathophysiological changes in the inflammatory process at the base of the coronary artery disease by non-invasive evaluation of endothelial function with positron emission tomography. He is particularly interested in developing a molecular imaging model to assess quantitatively the initial changes in the atherosclerotic process, which may help for an early, preclinical, diagnosis. As part of vascular biology characteristics, he is interested in applying new developed radioligands to target specific processes in the angiogenesis of cancer.

Dr. Pampaloni is published broadly and has spoken to national and international audiences on multiple topics in nuclear medicine and molecular imaging, especially quantitative myocardial blood flow and ischemic cardiomyopathy. He led the Nuclear Medicine section for a decade, during which time he directed the opening of operations at Mission Bay Hospital, helped to bring multiple new imaging and treatment agents to clinical practice, and guided the professional development of numerous highly successful residents, fellows and faculty. He has served as PI and co-investigator on multiple clinical trials and received numerous accolades for his scientific presentations.

Expertise:
Nuclear Medicine and Molecular Imaging and Theraputics

Specialty:
Oncology, pediatric oncology, cardiovascular

Professional Interests:
Functional and multimodality imaging, development of oncology related radioligands, solid pediatric tumors, angiogenesis, myocardial and neoplastic response to hypoxia

Education and Training:
• Medical School: Universidad Complutense School of Medicine, Madrid, Spain
• Internship: Imperial College, London - Cardiovascular Nuclear Medicine
• Residency: San Carlos Hospital, Madrid, Spain - Nuclear Medicine
• Residency: University of Pennsylvania School of Medicine - Nuclear Medicine
• Fellowship: UCLA David Geffen School of Medicine Department of Medical and Molecular Pharmacology - Cardiovascular Nuclear Medicine
• Fellowship: University of California, San Francisco Group for Leadership Collaborative Fellow
• Clinical Research Fellow: Imperial College, London - Cardiovascular Nuclear Medicine
• Doctor of Philosophy: Universidad Complutense School of Medicine, Madrid, Spain - Radiological Sciences
• Colegio Oficial de Medicos, Madrid, Spain
• Titulo de Especialista en Medicina Nuclear, Spain- Specialist Qualification in Nuclear Medicine
• Specialist Register in the United Kingdom in Nuclear Medicine
• General Medical Council, U.K.
• Michigan Board of Medicine
• Pennsylvania Controlled Substance Registration Certificate
• Pennsylvania State Board of Medicine
• California Medical Board
• California Controlled Substance Registration Certificate (active)
• American Board of Nuclear Medicine Board Certification
• Certification Board in Nuclear Cardiology
• Advanced Cardiac Life Support Certification (renewed)

Education

M.D., 1991 - School of Medicine, Universidad Complutense

Honors and Awards

Cardiovascular Young Investigator Award, Society of Nuclear Medicine Meeting, 2002
Best Communication Award, Spanish Society of Cardiology Annual Meeting, 1999

Publications

Hernandez Pampaloni M, Facchetti L, Nardo L. Pitfalls in [¹⁸F]FDG PET imaging in gynecological malignancies. Q J Nucl Med Mol Imaging. 2016 Jun; 60(2):124-38.
Pampaloni MH, Nazer B, Botvinick E. Erratum to: Isolated right ventricular cardiac sarcoidosis demonstrated by (18)FDG positron emission tomography. J Nucl Cardiol. 2015 Feb; 22(1):221.
Pampaloni MH, Nardo L. PET/MRI radiotracer beyond ¹⁸F-FDG. PET Clin. 2014 Jul; 9(3):345-9.
Hernandez Pampaloni M, Nazer B, Nazar B, Botvinick E. Isolated right ventricular cardiac sarcoidosis demonstrated by ¹⁸FDG positron emission tomography. J Nucl Cardiol. 2014 Jun; 21(3):652-4.